Back to Search Start Over

Sangamo secures $50M upfront in neurodegenerative pact with Roche's Genentech.

Authors :
Masson, Gabrielle
Source :
FierceBiotech; 8/6/2024, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

Sangamo Therapeutics has secured a $2 billion-plus pact with Genentech to develop intravenous genomic medicines for neurodegenerative diseases. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
ALZHEIMER'S disease
NEURODEGENERATION
GENE therapy
CELLULAR therapy
THERAPEUTICS

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
178912428

Tools

Authors Abstract Subjects Details